PubMed · 1993 · 10 citations · 0 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyGeneral PharmacologyPharmacodynamicsCardiovascular PharmacodynamicsCardiovascular PharmacologyHemodynamic PharmacologyVasodilator TherapyCardiovascular Drug PharmacologyChemical Agent SynthesisHemodynamic Drug EffectsHemodynamic Effects Of VasodilatorsLeft Ventricular Systolic FunctionMyocardial Oxygen ConsumptionTotal ResistanceVasodilator Pharmacology
Nipradilol (3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran) is a newly synthesized chemical agent designed to possess beta-adrenoceptor blocking and vasodilating actions. Nipradilol decreased left ventricular contractility index (Emax, slope of the ventricular end-systolic pressure-volume relation), systolic pressure-volume area (PVA, a measure of ventricular total mechanical energy) and oxygen consumption in cross-circulated excised dog hearts. However, nipradilol did not decrease total coronary resistance. These results indicate that nipradilol, like propranolol, depresses myocardial mechanoenergetics and that the vasodilating action of nipradilol could not be detected in the present study.